Artesunate- amodiaquine

Access

-

Approved

ASAQ Winthrop®

Sanofi

3-day cure, artemisinin-based combination therapies (TPP-1)

Therapeutic indication	Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5 kg
Dosing	Once-daily for 3 days
Efficacy	28-day PCR-corrected ACPR* 94.4%–98.9%
Key features	Lower price compared to other prequalified artemisinin-based combination therapies (public-sector tenders) 3-year shelf life
Challenges	Amodiaquine resistance in some countries Being withdrawn from countries where SPAQ is deployed for seasonal malaria chemoprevention (SMC) following WHO recommendation
Status	540 million treatments distributed since 2007 Approved in 33 countries
Previously	DNDi, Sanofi and partners completed development and registration Incorporated into MMV portfolio via collaboration supporting phase IV safety study in Côte d’Ivoire in 2010
Project Director	Adam Aspinall

* ACPR = adequate clinical and parasitological response